Both of these players are leaders in their fields.

Matthew Kapusta, CEO of uniQure N.V., sold 14,581 shares at $9.06 on March 4 for about $132,103, reducing his stake by 2.16%, according to a Form 4 filed with the U.S. Securities and Exchange ...

In this article, we will look at the 12 Cheap Biotech Stocks to Buy Now.

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...

Multibagger stock: Titan Biotech shares surged 20% to ₹312 after a 1:5 stock split, enhancing liquidity and making shares more affordable for retail investors. The small-cap stock has delivered ...

Intensity Therapeutics, Inc., a Shelton-based biotechnology company, has regained compliance with Nasdaq listing requirements, about three weeks after it executed a reverse-stock split. The company ...

X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...

Bristol Myers Squibb BMY and Amgen AMGN are among the largest global biotechnology companies with broad and diverse portfolios. Bristol Myers Squibb is focused on discovering, developing and ...

Bell Potter thinks this biotech could be working on something very big. The post Broker says this exciting ASX biotech stock could rise almost 50% appeared first on The Motley Fool Australia.

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has three promising candidates in early development as well as its only ...